Gross Profit Comparison: Amgen Inc. and Teva Pharmaceutical Industries Limited Trends

Amgen vs. Teva: A Decade of Diverging Profits

__timestampAmgen Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20141564100000011056000000
Thursday, January 1, 20151743500000011356000000
Friday, January 1, 20161882900000011859000000
Sunday, January 1, 20171878000000010825000000
Monday, January 1, 2018196460000008296000000
Tuesday, January 1, 2019190060000007536000000
Wednesday, January 1, 2020192650000007725000000
Friday, January 1, 2021195250000007594000000
Saturday, January 1, 2022199170000006973000000
Sunday, January 1, 2023197750000007646000000
Monday, January 1, 2024205660000008064000000
Loading chart...

Cracking the code

A Tale of Two Giants: Amgen Inc. vs. Teva Pharmaceutical Industries Limited

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their market position and future potential. Over the past decade, Amgen Inc. and Teva Pharmaceutical Industries Limited have showcased contrasting trends in their gross profit margins. From 2014 to 2023, Amgen Inc. has consistently demonstrated robust growth, with its gross profit increasing by approximately 26%, peaking in 2022. In contrast, Teva Pharmaceutical has faced challenges, with its gross profit declining by around 37% over the same period. This divergence highlights Amgen's strategic prowess in maintaining a competitive edge, while Teva navigates through industry hurdles. As we look to the future, these trends offer valuable insights into the strategic directions and market dynamics of these pharmaceutical titans.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025